244 related articles for article (PubMed ID: 23833270)
1. Interaction of 11C-tariquidar and 11C-elacridar with P-glycoprotein and breast cancer resistance protein at the human blood-brain barrier.
Bauer M; Karch R; Zeitlinger M; Stanek J; Philippe C; Wadsak W; Mitterhauser M; Jäger W; Haslacher H; Müller M; Langer O
J Nucl Med; 2013 Aug; 54(8):1181-7. PubMed ID: 23833270
[TBL] [Abstract][Full Text] [Related]
2. Assessment of cerebral P-glycoprotein expression and function with PET by combined [11C]inhibitor and [11C]substrate scans in rats.
Müllauer J; Karch R; Bankstahl JP; Bankstahl M; Stanek J; Wanek T; Mairinger S; Müller M; Löscher W; Langer O; Kuntner C
Nucl Med Biol; 2013 Aug; 40(6):755-63. PubMed ID: 23774004
[TBL] [Abstract][Full Text] [Related]
3. A comparative small-animal PET evaluation of [11C]tariquidar, [11C]elacridar and (R)-[11C]verapamil for detection of P-glycoprotein-expressing murine breast cancer.
Wanek T; Kuntner C; Bankstahl JP; Bankstahl M; Stanek J; Sauberer M; Mairinger S; Strommer S; Wacheck V; Löscher W; Erker T; Müller M; Langer O
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):149-59. PubMed ID: 21983837
[TBL] [Abstract][Full Text] [Related]
4. (R)-[(11)C]verapamil is selectively transported by murine and human P-glycoprotein at the blood-brain barrier, and not by MRP1 and BCRP.
Römermann K; Wanek T; Bankstahl M; Bankstahl JP; Fedrowitz M; Müller M; Löscher W; Kuntner C; Langer O
Nucl Med Biol; 2013 Oct; 40(7):873-8. PubMed ID: 23845421
[TBL] [Abstract][Full Text] [Related]
5. Radioligands targeting P-glycoprotein and other drug efflux proteins at the blood-brain barrier.
Wanek T; Mairinger S; Langer O
J Labelled Comp Radiopharm; 2013; 56(3-4):68-77. PubMed ID: 24285312
[TBL] [Abstract][Full Text] [Related]
6. Tariquidar and elacridar are dose-dependently transported by P-glycoprotein and Bcrp at the blood-brain barrier: a small-animal positron emission tomography and in vitro study.
Bankstahl JP; Bankstahl M; Römermann K; Wanek T; Stanek J; Windhorst AD; Fedrowitz M; Erker T; Müller M; Löscher W; Langer O; Kuntner C
Drug Metab Dispos; 2013 Apr; 41(4):754-62. PubMed ID: 23305710
[TBL] [Abstract][Full Text] [Related]
7. Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET.
Kuntner C; Bankstahl JP; Bankstahl M; Stanek J; Wanek T; Stundner G; Karch R; Brauner R; Meier M; Ding X; Müller M; Löscher W; Langer O
Eur J Nucl Med Mol Imaging; 2010 May; 37(5):942-53. PubMed ID: 20016890
[TBL] [Abstract][Full Text] [Related]
8. Radiosynthesis and in vivo evaluation of 1-[18F]fluoroelacridar as a positron emission tomography tracer for P-glycoprotein and breast cancer resistance protein.
Dörner B; Kuntner C; Bankstahl JP; Wanek T; Bankstahl M; Stanek J; Müllauer J; Bauer F; Mairinger S; Löscher W; Miller DW; Chiba P; Müller M; Erker T; Langer O
Bioorg Med Chem; 2011 Apr; 19(7):2190-8. PubMed ID: 21419632
[TBL] [Abstract][Full Text] [Related]
9. Interaction of HM30181 with P-glycoprotein at the murine blood-brain barrier assessed with positron emission tomography.
Bauer F; Wanek T; Mairinger S; Stanek J; Sauberer M; Kuntner C; Parveen Z; Chiba P; Müller M; Langer O; Erker T
Eur J Pharmacol; 2012 Dec; 696(1-3):18-27. PubMed ID: 23022332
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor.
Bauer F; Kuntner C; Bankstahl JP; Wanek T; Bankstahl M; Stanek J; Mairinger S; Dörner B; Löscher W; Müller M; Erker T; Langer O
Bioorg Med Chem; 2010 Aug; 18(15):5489-97. PubMed ID: 20621487
[TBL] [Abstract][Full Text] [Related]
11. Factors Governing P-Glycoprotein-Mediated Drug-Drug Interactions at the Blood-Brain Barrier Measured with Positron Emission Tomography.
Wanek T; Römermann K; Mairinger S; Stanek J; Sauberer M; Filip T; Traxl A; Kuntner C; Pahnke J; Bauer F; Erker T; Löscher W; Müller M; Langer O
Mol Pharm; 2015 Sep; 12(9):3214-25. PubMed ID: 26202880
[TBL] [Abstract][Full Text] [Related]
12. Dissimilar Effect of P-Glycoprotein and Breast Cancer Resistance Protein Inhibition on the Distribution of Erlotinib to the Retina and Brain in Humans and Mice.
Biali ME; Auvity S; Cisternino S; Smirnova M; Hacker M; Zeitlinger M; Mairinger S; Tournier N; Bauer M; Langer O
Mol Pharm; 2023 Nov; 20(11):5877-5887. PubMed ID: 37883694
[TBL] [Abstract][Full Text] [Related]
13. A novel PET protocol for visualization of breast cancer resistance protein function at the blood-brain barrier.
Wanek T; Kuntner C; Bankstahl JP; Mairinger S; Bankstahl M; Stanek J; Sauberer M; Filip T; Erker T; Müller M; Löscher W; Langer O
J Cereb Blood Flow Metab; 2012 Nov; 32(11):2002-11. PubMed ID: 22828996
[TBL] [Abstract][Full Text] [Related]
14. Whole-Body Distribution and Radiation Dosimetry of 11C-Elacridar and 11C-Tariquidar in Humans.
Bauer M; Blaickner M; Philippe C; Wadsak W; Hacker M; Zeitlinger M; Langer O
J Nucl Med; 2016 Aug; 57(8):1265-8. PubMed ID: 27081167
[TBL] [Abstract][Full Text] [Related]
15. A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET.
Wagner CC; Bauer M; Karch R; Feurstein T; Kopp S; Chiba P; Kletter K; Löscher W; Müller M; Zeitlinger M; Langer O
J Nucl Med; 2009 Dec; 50(12):1954-61. PubMed ID: 19910428
[TBL] [Abstract][Full Text] [Related]
16. Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET.
Bankstahl JP; Kuntner C; Abrahim A; Karch R; Stanek J; Wanek T; Wadsak W; Kletter K; Müller M; Löscher W; Langer O
J Nucl Med; 2008 Aug; 49(8):1328-35. PubMed ID: 18632828
[TBL] [Abstract][Full Text] [Related]
17. Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system.
Sane R; Agarwal S; Mittapalli RK; Elmquist WF
J Pharmacol Exp Ther; 2013 Apr; 345(1):111-24. PubMed ID: 23397054
[TBL] [Abstract][Full Text] [Related]
18. PET study on mice bearing human colon adenocarcinoma cells using [11C]GF120918, a dual radioligand for P-glycoprotein and breast cancer resistance protein.
Yamasaki T; Kawamura K; Hatori A; Yui J; Yanamoto K; Yoshida Y; Ogawa M; Nengaki N; Wakisaka H; Fukumura T; Zhang MR
Nucl Med Commun; 2010 Nov; 31(11):985-93. PubMed ID: 20859232
[TBL] [Abstract][Full Text] [Related]
19. Impact of P-gp and BCRP on pulmonary drug disposition assessed by PET imaging in rats.
Mairinger S; Hernández-Lozano I; Filip T; Sauberer M; Löbsch M; Stanek J; Wanek T; Sake JA; Pekar T; Ehrhardt C; Langer O
J Control Release; 2022 Sep; 349():109-117. PubMed ID: 35798092
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the P-glycoprotein- and breast cancer resistance protein-mediated brain penetration of 11C-labeled topotecan using small-animal positron emission tomography.
Yamasaki T; Fujinaga M; Kawamura K; Hatori A; Yui J; Nengaki N; Ogawa M; Yoshida Y; Wakizaka H; Yanamoto K; Fukumura T; Zhang MR
Nucl Med Biol; 2011 Jul; 38(5):707-14. PubMed ID: 21718946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
